Covid resources are essential to support Oxford / AstraZeneca jabs, new courses

The protection provided by two-dimensional Oxford / AstraZeneca coronavirus shots, including acute infections, begins to decline after three months of re-shooting, according to a new study showing the need for supportive programs.

The researchers analyzed information about 2m people in Scotland and 42m people in Brazil who received two shots of the vaccine. His findings were published in a a new peer-reviewed paper in The Lancet late Monday. The Omicron variant was not rotating during the study period.

“We found a lower immunity to the vaccine [the vaccine] against those who received Covid-19 hospitalization and died in Scotland and Brazil, this is evident within three months of the second vaccine, “he wrote.” [the vaccine]. ”

Researchers were able to compare Scottish-Brazilian data because the same three-month period was used between the Doses, and because those most at risk of disease and health workers were prioritized to vaccinate in both areas.

In the study, different strains of the virus – Delta in Scotland, Gamma in Brazil – revolved around the fact that, while vaccinated immunity, “probably” contributed to the decline in efficiency.

In the UK, where many received the AstraZeneca vaccine earlier this year, they have moved to give all seniors a shot of mRNA to prevent the spread of the Omicron virus.

Some rich countries have stepped up their advocacy programs to reduce the spread of the problem. Initially, preliminary evidence suggests that the commonly used vaccine releases less antibodies against Omicron than in previous models, and that a third shot of mRNA may increase their dose. However, it is not yet known how this translates to its effectiveness.

The head of the European drug regulator has said this it may take some time to agree on whether Omicron’s shooting would be necessary, the Financial Times reported Monday.

Scientists have long anticipated that the two shots will continue to protect against serious infections, since immunity is not limited to the number of antibodies. However, some experts who did not participate in the study complained that this could change the concept.

Peter English, a retired consultant on the management of infectious diseases, said the prevailing view was that protection against serious diseases and side effects, for example with T-cells, could continue, “perhaps for many years”.

“The paper raises doubts in this regard,” said English. “It shows a gradual decrease in the prevention of serious infections over time, and the risk of infection increases fivefold, compared with newly vaccinated, within a few months.”

“This is very difficult,” he said. “In the short term, it emphasizes the need for additional doses, and over time or over time raises questions about how modern vaccines can prevent future infections.”

An outside expert, Penny Ward, a visiting professor of medicine at King’s College London, said there was still a “permanent vaccine” to prevent hospitalization and Covid mortality of at least 50 percent in the follow-up period. But he conceded that a boosting shot was needed to provide greater security.

Aziz Sheikh, co-author of the study and director of the Usher Institute at the University of Edinburgh, said that recognizing when the decline began for those who received the AstraZeneca vaccine, “it should be possible for governments to develop proactive programs that would reflect AstraZeneca vaccine safety.” .

“If you are eligible for treatment and you have not, I suggest you book a book as soon as possible,” he said.

Pascal Soriot, CEO of AstraZeneca, was last month He also said that using the vaccine could help prevent serious diseases in the elderly for a long time. He said, however, there was no evidence and additional data was needed.

Oxford and AstraZeneca did not respond to a request for comment.